Intensive BP Targets Cut Events in Stroke and Diabetes but Raise Renal Monitoring Needs

The REDUCE trial, presented as an abstract at the AHA meeting, randomized patients immediately after stroke to early spironolactone versus usual care. At three months the intervention arm achieved greater rates of BP below 130/80 mm Hg, consistent with prior observational data linking each 7 mm Hg systolic reduction to roughly 38 percent lower recurrent stroke risk. The approach leverages an inexpensive, widely available diuretic typically reserved for resistant hypertension. OPTIMAL-STROKE enrolled a larger Brazilian cohort and tested the lower 120 mm Hg systolic goal. Over four years the intensive arm recorded fewer composite events including recurrent stroke, myocardial infarction, and heart-failure hospitalization, though electrolyte shifts and modest renal-function changes required closer laboratory surveillance. No increase in end-stage renal disease or dialysis occurred. Contextual analysis reveals persistent real-world gaps: one-third of stroke survivors fail guideline targets and one-fifth discontinue antihypertensives within a year. Adding spironolactone earlier may address adherence barriers, yet the unpublished REDUCE data and short-term surrogate endpoint leave outcome confirmation pending. OPTIMAL-DIABETES extends the same target to diabetes, underscoring cross-specialty coordination between neurology, endocrinology, and primary care.